Hanmi and SK will develop generics of Xarelto
It is observed that the generic of the 2nd generation anticoagulant ‘Xarelto’ is being developed.
It is known that the owner company of ‘Xarelto’, Bayer Korea, acquired an approval for the bioequivalence test plan to develop the generic.
According to the Ministiry of Food and Drug Safety, SK Ch...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
